Brain Neoplasm Clinical Trial
Official title:
Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery
Verified date | July 2020 |
Source | Aga Khan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Several modalities have been studied to prevent coughing during emergence, including extubation in a deep plane of anesthesia but have proved to be unreliable. So far, no reliable method is recommended as standard of care. The advantages of administering tramadol includes a long duration of action, rapid recovery, limited depression of respiratory function and no effect on platelet makes it a safe medication to use for neurosurgical patients after craniotomy. The primary objective of the study is to observe the effect of single dose of tramadol (1mg/kg) administered 45 minutes before extubation on hemodynamic response (measurement of B.P and H.R) during extubation.
Status | Completed |
Enrollment | 80 |
Est. completion date | December 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients with craniotomy for supratentorial tumors under general anesthesia - American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients - Elective surgery - Patients with Glasgow Coma Scale (GCS) 15/15 Exclusion Criteria: - Patients with a history of allergy or hypersensitivity to tramadol. - History of epilepsy or convulsions due to any reason. - Chronic usage of analgesic drugs. - Patients using monoamine oxidase inhibitors. - Patients with clinical signs of raised ICP. - Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2) - Language barrier. - Patients taking B-blockers or Ca channel blockers. - Patients above 65 years of age ( Physiology difference) |
Country | Name | City | State |
---|---|---|---|
Pakistan | Aga Khan University | Karachi | Sindh |
Lead Sponsor | Collaborator |
---|---|
Aga Khan University |
Pakistan,
Ferber J, Juniewicz H, Glogowska E, Wronski J, Abraszko R, Mierzwa J. Tramadol for postoperative analgesia in intracranial surgery. Its effect on ICP and CPP. Neurol Neurochir Pol. 2000;34(6 Suppl):70-9. — View Citation
Lin BF, Ju DT, Cherng CH, Hung NK, Yeh CC, Chan SM, Wu CT. Comparison between intraoperative fentanyl and tramadol to improve quality of emergence. J Neurosurg Anesthesiol. 2012 Apr;24(2):127-32. doi: 10.1097/ANA.0b013e31823c4a24. — View Citation
Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther. 1999 Apr;37(4):175-83. — View Citation
Mikawa K, Nishina K, Maekawa N, Obara H. Attenuation of cardiovascular responses to tracheal extubation: verapamil versus diltiazem. Anesth Analg. 1996 Jun;82(6):1205-10. — View Citation
Neelakanta G, Miller J. Minimum alveolar concentration of isoflurane for tracheal extubation in deeply anesthetized children. Anesthesiology. 1994 Apr;80(4):811-3. — View Citation
Rahimi SY, Alleyne CH, Vernier E, Witcher MR, Vender JR. Postoperative pain management with tramadol after craniotomy: evaluation and cost analysis. J Neurosurg. 2010 Feb;112(2):268-72. doi: 10.3171/2008.9.17689. — View Citation
Sudheer PS, Logan SW, Terblanche C, Ateleanu B, Hall JE. Comparison of the analgesic efficacy and respiratory effects of morphine, tramadol and codeine after craniotomy. Anaesthesia. 2007 Jun;62(6):555-60. — View Citation
Valley RD, Ramza JT, Calhoun P, Freid EB, Bailey AG, Kopp VJ, Georges LS. Tracheal extubation of deeply anesthetized pediatric patients: a comparison of isoflurane and sevoflurane. Anesth Analg. 1999 Apr;88(4):742-5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Haemodynamic Parameters at the Time of Emergence and Postextubation | Systolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. | Systolic BP from the time of extubation till 6 hours post operatively | |
Primary | Haemodynamic Parameters at the Time of Emergence and Postextubation | Heart rate will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If haemodynamic values of heart rate rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. | HR from the time of extubation till 6 hours post operatively | |
Primary | Haemodynamic Parameters at the Time of Emergence and Postextubation | Diastolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. | Diastolic BP from the time of extubation till 6 hours post operatively | |
Secondary | Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Cough on Cough Scale. | Cough will be described on following scale 5 = No coughing or straining, 4 = Very smooth minimal coughing, 3 = Moderate coughing, 2 = Marked coughing or straining, 1 = Poor extubation Cough will be recorded on the above mentioned scale by resident/consultant at following time intervals of emergence At resumption of spontaneous breathing, Ability to respond to verbal commands At cuff deflation At extubation 2 minutes after extubation. It will be noted if it occurs during emergence at the above mentioned time intervals. Absence of it will be considered as smooth emergence. |
Cough at the time of emergence | |
Secondary | Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Laryngospasm and Bronchospasm. | If there is any episode of bronchospasm or laryngospasm, it will be noted if it occured during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence | at the time of extubation till 6 hours postoperatively | |
Secondary | Measure the Quality of Emergence From General Anaesthesia by Measuring Sedation Score | If there is any episode of sedation it will be noted if it occurs during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence. sedation score will be used as 0= no sedation, 1= mildly sedated (eye opening on verbal commands), 2= moderately sedated ( awakens on giving pain), 3= deeply sedated ( not waking up even on pain) |
at the time of extubation till 6 hours postoperatively | |
Secondary | Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring PONV | Post operative nausea vomiting will be recorded at RR, 2, 4 and 6 hours postoperatively. If there is any episode of PONV it will be noted. Absence of it will be considered as smooth emergence | at Recovery Room , 2, 4 and 6 hours postoperatively | |
Secondary | Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring Convulsions | Convulsions will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively.If there is any episode of convulsion, it will be noted. Absence of it will be considered as smooth emergence. | at Recovery Room, 2, 4 and 6 hours postoperatively | |
Secondary | Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring GCS | Post operative Glasgow Coma Scale (GCS) will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively. If there is any deterioration in GCS less than 8/15, Patients will be intubated. GCS categories <8 Low GCS 9-12 Intermediate GCS 13-15 Full GCS |
at Recovery Room, 2, 4 and 6 hours postoperatively | |
Secondary | Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Mointoring Requirement of Analgesia | Requirement of analgesia will be recorded at recovery room, 2, 4 and 6 hours postoperatively. If there is any need of analgesic, it will be noted and will be considered as one of the determinants of poor quality of emergence. | At Recovery room, 2, 4 and 6 hours postoperatively | |
Secondary | Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Episodes of Denaturation | If there is any episodes of denaturation (Oxygen saturation <92%), it will be noted it it is occurring during emergence. Absence of it will be considered as smooth emergence |
at the time of extubation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001972 -
PET Scan of Brain Metabolism in Relation to Age and Disease
|
N/A | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Withdrawn |
NCT03234309 -
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00178295 -
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
|
N/A | |
Recruiting |
NCT04810871 -
Surgical Resection of Latent Brain Tumors Prior to Recurrence
|
N/A | |
Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00040573 -
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
Recruiting |
NCT03216148 -
18F-FET PET in Childhood Brain Tumours
|
Phase 2 | |
Completed |
NCT00001171 -
Evaluation of Factors in Human Brain Tumors
|
N/A | |
Withdrawn |
NCT01413438 -
Bevacizumab With or Without Surgery for Adult Glioblastomas
|
Phase 2 | |
Not yet recruiting |
NCT05516485 -
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
|
N/A | |
Recruiting |
NCT02639325 -
Tumor Related Epilepsy
|
||
Recruiting |
NCT02672995 -
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
|
Phase 1 |